Affichage 1 à 7 des 7 essais cliniques
ESSAI CLINIQUE No essai ClinicalTrials.gov ID |
Investigateur(trice) principal(e)
Coordonnateur(rice) |
||
---|---|---|---|
(EN) A Phase 1 Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
LOXO-IDH-20001 NCT04603001 ![]() |
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
![]() |
Leucémie myéloïde aiguë (LMA) Syndrome myélodysplasique |
Dre Sarit Assouline |
Registre de l’hémoglobinurie paroxystique nocturne (HPN)
Registre PNH (M07-001) NCT01374360 ![]() |
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
![]() |
Syndrome myélodysplasique |
Dr Thomas KIss Johanne Blais 514-252-3400 poste 3295 |
(EN) A Phase 2/3, Multicenter, Randomized, Dose Optimization (Part I), Double-blind (Part II) Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With IPSS-R Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)
CA055-026 NCT05469737 ![]() |
CENTRE UNIVERSITAIRE DE SANTE MCGILL
![]() |
Syndrome myélodysplasique |
Dr John Storring Judit Kokai 438-888-1582 |
(EN) Extended Access of Momelotinib for Subjects With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
GS-US-352-4365 NCT03441113 ![]() |
CENTRE UNIVERSITAIRE DE SANTE MCGILL
![]() |
Syndrome myélodysplasique |
Dr Jonathan How Judit Kokai 438-888-1582 |
Registre Canadien de la SMD
Registre SMD ![]() |
CHU DE QUEBEC – UNIVERSITE LAVAL
![]() |
Syndrome myélodysplasique |
Dr Robert Delage Linda Vallée 418-649-0252 poste 66602 |
(EN) A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome
SELECT MDS-1 NCT04797780 ![]() |
CENTRE UNIVERSITAIRE DE SANTE MCGILL
![]() |
Syndrome myélodysplasique |
Dr John Storring Judit Kokai 438-888-1582 |
(EN) A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
CR107947 NCT02598661 ![]() |
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
![]() |
Syndrome myélodysplasique |
Dre April Shamy Erika Thibault 514-340-8222 |